secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2026-08-05T20:06:23+00:00
Accession:  0001193125-26-335056
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta Q2 net product revenue $328.7M; GAAP operating income $13.3M; narrows FY2026 guidance
--------------------------------------------------------------------------------

- Net product revenue $328.7M: PMO $230.6M, ELEVIDYS $98.1M; total revenue $401.3M, down 34% YoY.
- GAAP net loss $4.9M ($0.05 diluted loss); non-GAAP net income $78.6M ($0.64 diluted EPS).
- Narrowed FY2026 net product revenue guidance to $1.2-$1.3B; non-GAAP R&D+SG&A to $800-$850M.
- Appointed Michael Severino, MD, as CEO effective July 28, 2026; Doug Ingram retired.
- Cash, equivalents, restricted cash and investments $945M, up ~$197M in the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/0001193125-26-335056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer